<code id='717AB10078'></code><style id='717AB10078'></style>
    • <acronym id='717AB10078'></acronym>
      <center id='717AB10078'><center id='717AB10078'><tfoot id='717AB10078'></tfoot></center><abbr id='717AB10078'><dir id='717AB10078'><tfoot id='717AB10078'></tfoot><noframes id='717AB10078'>

    • <optgroup id='717AB10078'><strike id='717AB10078'><sup id='717AB10078'></sup></strike><code id='717AB10078'></code></optgroup>
        1. <b id='717AB10078'><label id='717AB10078'><select id='717AB10078'><dt id='717AB10078'><span id='717AB10078'></span></dt></select></label></b><u id='717AB10078'></u>
          <i id='717AB10078'><strike id='717AB10078'><tt id='717AB10078'><pre id='717AB10078'></pre></tt></strike></i>

          Home / Wikipedia / explore

          explore


          explore

          author:leisure time    Page View:14293
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In